Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Artif Cells, Nanomedicine, Biotechnology (2024) 52(1):13144
First approved to treat MDS-related anemia in 2020 in patients who failed to respond to an erythropoiesis-stimulating (ESA) agentthe established front-line treatmentthe treatment will now be available to patients who have not received ESA therapy
Contents undamaged
April 26 Product: Pfizers Beqvez Indication: Hemophilia B People with moderate to severe hemophilia B have a new, one-time treatment option Friday, as the FDA approved Pfizers Beqvez
US$ 26.13
US$ 23.28
US$ 21.91
